Mereo BioPharma Group plc
MREO
$0.32
$0.013.64%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -50.00% | -50.00% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -50.00% | -50.00% | -- |
| Cost of Revenue | -- | -- | 148.35% | 125.98% | -- |
| Gross Profit | -- | -- | -71.09% | -75.60% | -- |
| SG&A Expenses | -28.93% | -12.95% | 7.17% | 10.16% | 55.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -23.03% | -15.22% | 17.34% | 15.97% | 32.71% |
| Operating Income | 24.09% | 16.31% | -19.11% | -17.71% | -84.45% |
| Income Before Tax | 24.33% | 3.18% | 9.32% | -32.56% | -75.59% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 24.33% | 3.18% | 8.26% | -34.48% | -79.14% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 24.33% | 3.18% | 8.26% | -34.48% | -79.14% |
| EBIT | 24.09% | 16.31% | -19.11% | -17.71% | -84.45% |
| EBITDA | 24.97% | 17.05% | -19.63% | -17.96% | -86.64% |
| EPS Basic | 28.31% | 10.07% | 15.84% | -20.43% | -63.27% |
| Normalized Basic EPS | 28.29% | 10.11% | 16.94% | -18.67% | -60.00% |
| EPS Diluted | 28.31% | 10.07% | 15.84% | -20.43% | -63.27% |
| Normalized Diluted EPS | 28.29% | 10.11% | 16.94% | -18.67% | -60.00% |
| Average Basic Shares Outstanding | 5.27% | 7.67% | 9.60% | 11.87% | 12.08% |
| Average Diluted Shares Outstanding | 5.27% | 7.67% | 9.60% | 11.87% | 12.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |